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Abstract
Background & Aims: There have been many studies on plasma butyrylcholinesterase in liver dysfunction. However, no data
is available about acetylcholinesterase in human cirrhosis, although profound changes have been described in cirrhotic rat
models.
Methods: Human serum and liver acetylcholinesterase and its molecular forms were determined enzymatically, after
butyrylcholinesterase immunodepletion. The distinct species of acetylcholinesterase, with a distinct C-terminus, were
determined by western blotting, and the level of liver transcripts by real-time PCR. Liver acetylcholinesterase was also
evaluated by immunocytochemistry.
Results: In patients with liver cirrhosis, the activity of plasma acetylcholinesterase (rich in light species), appeared to be
apparently unaffected. However, the levels of the soluble readthrough (R) acetylcholinesterase form, an acetylcholinesterase
species usually associated with stress and pathology, was increased compared to controls. Human liver acetylcholinesterase
activity levels were also unchanged, but protein levels of the acetylcholinesterase-R and other acetylcholinesterase subunit
species were increased in the cirrhotic liver. This increase in acetylcholinesterase protein expression in the cirrhotic liver was
confirmed by PCR analysis. Immunohistological examination confirmed that acetylcholinesterase immunoreactivity is
increased in parenchymal cells of the cirrhotic liver.
Conclusions: We demonstrate significant changes in acetylcholinesterase at the protein and mRNA levels in liver cirrhosis,
with no difference in enzymatic activity. The altered expression of acetylcholinesterase protein may reflect changes in its
pathophysiological role.
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Introduction
Cholinesterases are a family of ubiquitous enzymes frequently
studied in association with many pathological processes. Acetyl-
cholinesterase (EC 3.1.1.7; AChE), the enzyme chiefly responsible
for the inactivation of cholinergic neurotransmission, has been
associated to cognitive dysfunction in Alzheimer’s disease [1], and
to disorders such as neuromuscular dysfunction and myasthenic
syndromes, tumorigenesis among many others (for a review see
[2,3,4]). AChE is present in serum and liver, however its
physiological significance other than inactivating acetylcholine
has thus far not been elucidated. Thus, roles for AChE other than
its acetylcholine hydrolytic activity have been proposed [2,3,4]. A
second cholinesterase, butyrylcholinesterase (EC 3.1.1.8; BChE),
whose physiological role is also unknown, co-exists with AChE in
many tissues, including those with no cholinergic function [2,5].
The two cholinesterases are regulated by separate mechanisms
[6,7]. Although very few studies have addressed the levels of
cholinesterase in human liver [8,9], it is widely accepted that
plasma BChE originates in liver cells and represents the major
cholinesterase in human serum, approximately 160 times higher
than AChE [10]. Consequently, previous studies on cholinesterase
changes during liver dysfunction have focussed on serum BChE;
whereas AChE has not received much attention. Indeed, the use of
serum BChE activity as an indicator of liver function has been
employed for decades [11].
So far, the study of AChE in pathological liver has been
restricted to hepatocellular carcinoma [12] or to animal models
that have less BChE than AChE activity [13]. Using the rat as an
animal model with low serum BChE activity, we have reported
that AChE is significantly altered during liver cirrhosis [13].
However, the contribution of AChE and BChE and their different
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molecular forms varies between rats and humans, and to date,
there is no data on potential alterations of AChE expression in the
cirrhotic human liver.
Classical studies on cholinesterase usually focus on enzymatic
activity and molecular forms of the enzyme. AChE occurs as both
active and inactive subunits [14,15,16]. Different AChE species
are derived from alternative RNA splicing, generating different
polypeptide transcripts with the same catalytic domain, but with
distinct C-termini. It would be useful to perform further western
blot analyses using different anti-AChE antibodies raised against
different C-terminal peptides. In this study, we have measured
AChE activity in non-diseased and cirrhotic human liver and
plasma after BChE removal by immunoprecipitation. We have
compared the different molecular forms and subunit banding
pattern of AChE by SDS-PAGE under reducing conditions
followed by Western blotting. AChE expression was assessed by
quantitative RT-PCR analysis of the different AChE mRNAs, and
the distribution of AChE protein was investigated in normal and
cirrhotic human liver by immunohistochemistry.
Patients and Methods
Patients
For this study we obtained ethics approval from the ethics
committee at our institutions (Universidad Miguel Herna´ndez,
Elche, and Hospital Clı´nic, Barcelona) and obtained written
informed consent from all involved participants. The study was
carried out in accordance with the Declaration of Helsinki.
Plasma samples from patients with liver cirrhosis and age-
matched controls were provided by the Hospital General
Universitario de Alicante (Spain), as previously described [17].
Causes of cirrhosis were alcoholism, Hepatitis C virus (HCV)
infection and both alcoholism and HCV. Plasma was separated
from whole blood by centrifugation, aliquoted and frozen at
280uC until use.
Liver samples were obtained from the Hospital Clinic of
Barcelona (Spain) and collected as described in a previous study
[18]. Fragments of normal liver adjacent to colon cancer
metastasis and liver specimens obtained immediately after
laparotomy and before vascular clamping were collected as
control cases. All controls had normal serum aminotransferase
levels and normal liver histology. Cirrhotic human samples were
obtained from liver explants after transplantation in patients with
chronic HCV-induced liver disease, from percutaneous liver
biopsy of patients with detectable serum RNA HCV and increased
alanine aminotransferase levels, and from resections of hepato-
carcinoma in cirrhotic patients.
Tissue homogenization and cholinesterase extraction
For cholinesterase extraction, small pieces of liver stored at
280uC were thawed slowly at 4uC and homogenized (10% w/v) in
ice-cold Tris-saline buffer (50 mM Tris-HCl, 1 M NaCl, and
50 mM MgCl2, pH 7.4) containing 0.5% (w/v) Triton X-100 and
supplemented with a cocktail of proteinase inhibitors [19]. The
suspension was then centrifuged at 100,0006g for 1 hr at 4uC to
recover a cholinesterase rich fraction.
BChE immunoprecipitation
In plasma and liver samples BChE was immunoprecipitated by
two successive incubations using an anti-BChE coupled affinity
resin (protein A-Sepharose with an anti-BChE polyclonal antibody
generously provided by Prof. Oksana Lockridge, University of
Nebraska Medical Center, Omaha, NE, USA), as previously
described [10]. The two successive incubations with the anti-
BChE resin ensured that the majority of the BChE activity in the
samples was removed. Plasma and liver samples immunodepleted
of BChE were then used for AChE determination.
Enzyme assays and protein determination
AChE and BChE activity were determined by a modified
microassay method of Ellman [10]. AChE was assayed with 1 mM
acetylthiocholine and 50 mM tetraisopropyl pyrophosphoramide
(Iso OMPA), a specific inhibitor of BChE; while BChE was
measured with 1 mM butyrylthiocholine and 10 mM BW284c51,
a specific inhibitor of AChE. One milliunit (mU) of AChE or
BChE activity was defined as the number of nmoles of
acetylthiocholine or butyrylthiocholine hydrolysed per min at
22uC. Protein concentrations were determined using the bicinch-
oninic acid method, with bovine serum albumin as standard
(Pierce, Rockford, IL).
Sedimentation analysis
Molecular forms of AChE and BChE were separated according
to their sedimentation coefficients by centrifugation on 5–20% (w/
v) sucrose gradients containing 0.5% (w/v) Triton X-100, as
previously described [20]. Approximately 40 fractions were
collected from the bottom of each tube and assayed for
cholinesterase activities. The cholinesterases present in liver and
plasma are mainly tetramers (G4) and light globular species
(dimers, G2, and monomers, G1).
Detection of AChE by Western Blotting
AChE subunits were detected by immunoblotting under
denaturing and reducing conditions. As plasma samples contain
high amounts of certain plasma proteins (albumin, immunoglob-
ulins, transferrin etc.), these were first depleted by immunoaffinity-
based chromatography (SepproH IgY14 spin column kit, GenWay
Biotech Inc, San Diego, CA) prior to electrophoresis. Samples
from plasma (25 mg of protein after protein depletion) and liver
(50 mg) were resolved by electrophoresis on 10% SDS-polyacryl-
amide slab gels. Following electrophoresis, proteins were blotted
onto nitrocellulose membranes, blocked with 5% bovine serum
albumin and incubated overnight with different anti-AChE
antibodies: N-19 (Santa Cruz Biotechnology), Ab31276 (Abcam,
Cambridge, UK), an antibody raised to the unique C-terminus of
human AChE-R ([21], a generous gift from Prof. Hermona Soreq,
The Institute of Life Sciences, The Hebrew university of
Jerusalem, Jerusalem, Israel), and T548, a polyclonal rabbit anti-
mouse AChE antibody raised against a recombinant AChE
protein made in mammalian HEK cells and corresponding to
mouse AChE sequence truncated at residue 548 ([22], generously
provided by Prof. Palmer Taylor; Department of Pharmacology,
Skaggs School of Pharmacy and Pharmaceutical Sciences,
University of California, San Diego, La Jolla, California, USA).
Nitrocellulose strips were then incubated with HRP-conjugated
secondary antibodies (Santa Cruz Biotechnology) and immunore-
active AChE was detected using the ECL-Plus kit (Amersham Life
Science, Arlington Heights, IL) in a Luminescent Image Analyzer
LAS-1000 Plus (FUJIFILM). Molecular weight markers were used
to determine protein size (Sigma-Aldrich Co, St. Louis, MO). For
semi-quantitative analysis, the intensity of AChE bands was
determined with the Science Lab Image Gauge v4.0 software
provided by FUJIFILM.
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RNA isolation and analysis of AChE transcripts by QRT-
PCR
Total RNA was extracted using the TRIzol reagent (Invitro-
genTM, Carlsbad, CA) according to the manufacturer’s protocol.
Five hundred nanograms of RNA were retro-transcribed using a
high capacity complementary DNA reverse transcription kit
(Applied Biosystems). Quantitative PCR amplification was per-
formed using a StepOneTM Real-Time PCR System (Applied
Biosystems, Foster City, CA) with Power SYBRH Green PCR
Master Mix according to the manufacturer’s instructions (see
primer sequence in the legend of Fig. 3). Transcript levels for
AChE (R, T and H transcripts) were calculated using the relative
standard curve method normalized to GAPDH.
AChE immunocytochemistry
Paraffin-embedded 3 mM liver sections were incubated with
goat anti-human AChE (N19, 1:100, Santa Cruz Biotetechnology,
SC6431) overnight. After extensive washing with PBS, sections
were incubated with a polyclonal rabbit anti-goat antibody
conjugated to HRP (1:600, Dako, E0466). Following further
washing in PBS, a secondary goat anti-rabbit antibody conjugated
to HRP (DAKO EnVision System-HRP, K4007) was added for
30 minutes at room temperature. 3,39 diaminobenzidine (DAB,
Dako) was used as a chromogen, and sections were counterstained
with hematoxilin. As negative controls, all specimens were
incubated with isotype-matched primary antibodies.
Statistical analysis
Measurements are expressed as means 6 SEM. Data was
analyzed by a Student’s t-test (two tailed) for single pair-wise
comparisons using SigmaStat (Version 2.03; SPSS Inc.) software.
Statistical significance was designated as p,0.05.
Results
AChE and BChE activities are routinely measured in the same
extract using specific substrates and inhibitors. However, the
elevated levels of BChE in human plasma are expected to interfere
in the determination of AChE, even in presence of BChE
inhibitors [13]. Thus, in order to estimate subtle changes in plasma
AChE levels from patients with cirrhotic liver conditions, we
measured AChE activity in plasma, after two cycles of BChE
immunoprecipitation [13]. No apparent differences in AChE
activity were observed in plasma from cirrhotic patients compared
to controls (Fig. 1A). BChE activity levels were lower in CL
samples prior to immunodepletion compared to controls (34%
decrease; p = 0.008) (Fig. S1A).
Both AChE and BChE are expressed as several molecular forms
distinguishable by their molecular weights [23]. Plasma superna-
tants before and after BChE-immunodepletion were fractionated
on sucrose density gradients to separate the different AChE
molecular forms. No difference was observed in the amount of the
major G1+G2 AChE species, nor in the minor G4 form from CL
plasma compared to controls (Fig. 1B). In undepleted plasma, the
major G4 form of BChE displayed a decrease in levels in parallel
with a decrease in total BChE activity (Fig. S1B).
Isoforms of AChE containing the same catalytic domain, but
with distinct C-terminal peptides, are generated by alternative
RNA splicing [4,23]. This alternative splicing is differentially
regulated in different cell types, at both the mRNA and post-
translational level. We have recently demonstrated the presence of
type T (‘tailed’) and type R (‘readthrough’) AChE subunits in
human plasma using different anti-AChE antibodies raised against
different C-terminal peptides. The third subunit, type H (‘hydro-
phobic’) is not able to be detected due to the lack of specific
antibodies [10]. We have also analyzed the complex banding-
pattern of the different AChE subunits by SDS-PAGE/Western
blotting using these different anti-AChE antibodies (Fig. 1C). The
antibody N-19, raised against a peptide that maps to the N-
terminus of human AChE, common to all subunits, detected three
major bands of approximately 78, 66 and 55 kDa. An alternative
anti-AChE antibody, T548, which specificity has recently dem-
onstrated in brain extracts from wild-type and knockout AChE
mice [24], allowed us to ensure the true identity of lighter AChE
subunits (Fig. S2). A similar pattern of AChE labelling was
demonstrated with an alternate anti-AChE antibody ab31276,
which recognizes the C-terminal of the AChE T subunits. No
difference in immunoreactivity of the predominant and more
clearly defined 55 kDa subunit was observed between pathological
and non-diseased samples (Fig. 1C). Interestingly, the antibody to
the R-AChE subunits, directed to the unique C-terminus of
AChE-R, and which only detects a 55 kDa band similar in size to
the T-subunit, displayed a significant increase in immunoreactivity
in cirrhotic samples (47% increase; p = 0.03) (Fig. 1C).
Figure 1. Increased levels of the acetylcholinesterase-R (AChE-
R) in plasma from individuals with cirrhotic livers. Plasma from
non-diseased controls (NL; n = 12, N) and cirrhotic individuals (CL; #;
n = 8) was immunoprecipitated with anti-BChE antibody and total AChE
activity levels (A) and AChE molecular forms levels (monomers and
dimmers: G1+G2) (B) were determined after immunoprecipitation. (C)
Immunodetection of AChE using denaturing conditions was performed
with an antibody raised against the N-terminus of AChE, common to all
AChE subunits. For densitometric quantification, antibodies raised to
the unique C-terminus of AChE-T and AChE-R subunits were used. a.u.:
arbitrary units. Columns represent means 6 SEM. *p,0.05.
doi:10.1371/journal.pone.0044598.g001
R-AChE in Liver Cirrhosis
PLOS ONE | www.plosone.org 3 September 2012 | Volume 7 | Issue 9 | e44598
The levels of BChE and AChE after BChE immunodepletion
were measured in the liver of cirrhotic patients to examine changes
in cholinesterase levels. Despite a decrease in BChE in the
cirrhotic liver (50% decrease; p= 0.002; Fig. S3A), no significant
change in AChE levels was observed (Fig. 2A). Tetrameric and
light molecular species of BChE were both decreased in cirrhotic
individuals (Fig. S3B); whereas the amount of monomeric AChE
was indistinguishable from amounts in the control group (Fig. 2B).
When liver extracts of AChE were analyzed by Western blotting
using the N-19 antibody, the three typical AChE bands (55, 66
and 78 kDa) were characterized (Fig. 2C). Immunoblotting with
the ab31276 antibody, specific for AChE T subunits, demonstrat-
ed an increase in the 55 kDa immunoreactive band in cirrhotic
extracts (119% increase; p= 0.03; Fig. 2C). In cirrhotic samples,
the antibody to R-AChE also displayed a significant increase in
immunoreactivity (128% increase; p,0.001) (Fig. 2C).
Quantitative RT-PCR analysis of AChE mRNA in liver
extracts from cirrhotic patients demonstrated an increase in levels
of the T-transcript (which encodes subunits which produce
monomeric and tetrameric forms), compared to controls (108%
increase; p = 0.03; Fig. 3). Similarly, and in agreement with
Western blot analysis data, levels of the R-transcript, which
encodes monomeric soluble subunits, were also increased in
cirrhotic livers compared to controls (113% increase; p = 0.01;
Fig. 3). RT-PCR analysis was used to determine the mRNA levels
for the minor splice variant, the AChE H-transcript. Levels of the
H-transcript were also increased in the cirrhotic liver (146%
increase; p= 0.03; Fig. 3). In summary, while enzyme levels remain
unchanged, expression levels of the different AChE variants are
substantially altered in liver cirrhosis.
Finally, the distribution of AChE-positive cells in the rat liver is
demonstrated by immunocytochemistry using the N-19 antibody.
While AChE was barely detected in normal human livers, it was
clearly observed in parenchymal cells in cirrhotic livers (Fig. 4), in
particular, in hepatocytes at the periphery of regenerative nodules.
Hepatic protein expression of the AChE subtypes could not be
determined as no subtype-specific antibodies are available for
immunocytochemistry.
Discussion
In this study, a significant change in AChE was observed at both
protein and mRNA levels in the cirrhotic human liver, while
enzyme activity was unchanged compared to controls. Increase in
AChE protein levels was also confirmed by immunohistological
examination. Similarly, in the serum of cirrhotic subjects, AChE
activity remained unchanged, while protein levels of the soluble
AChE-R was increased. The increase in the level of AChE protein
was associated by decrease in BChE activity in both serum and
cirrhotic liver.
Serum BChE activity levels have been widely used as a test of
liver function. Only few studies including a low number of patients
have assessed cholinesterase levels in human liver [8,9], and to the
best of our knowledge, no study has included cirrhotic patients. In
addition, conventional protein tissue extraction techniques grossly
Figure 2. Increased levels of acetylcholinesterase (AChE)
protein levels in liver extracts form cirrhotic individuals. Liver
extracts from non-diseased (NL; &; n = 6) and cirrhotic liver cases (CL;
%; n = 6) were immunodepleted of major butyrylcholinesterase (BChE)
activity, and total AChE activity levels (A) and AChE molecular species
(monomers and dimmers: G1+G2) (B) were determined after BChE
depletion. (C) Samples were immunoblotted under denaturing
conditions with different anti-AChE antibodies. The N-terminal anti-
body, which recognizes all AChE subunits, and antibodies directed to
the different C-termini of the AChE species (AChE-R and T subunits),
were used for densitometric quantification. * p,0.05.
doi:10.1371/journal.pone.0044598.g002
Figure 3. Increased levels of acetycholinesterase (AChE) mRNA
variants in cirrhotic liver. Relative mRNA levels of the liver
transcripts for AChE (T, R and H; labelled AChE-T, AChE-R and AChE-H
in the figure) were analyzed by QRT-PCR in non-diseased (NL;&; n = 5)
and cirrhotic liver cases (CL;%; n = 9). The selected primers were: AChE-
T transcript: Fw: 59-CTTCCTCCCCAAATTGCTC3-9 , Rev: 59-
TCCTGCTTGCTGTAGTGGTC-39 ; AChE-R transcr ipt : Fw: 59 -
CTTCCTCCCCAAATTGCTC-39, Rev: 59-GGGGAGAAGAGAGGGGTTAC-39;
AChE-H transcript: Fw: 59-CAATGAGCCCCGAGACC-39, Rev: 59-
GAGCCTCCGAGGCGGTG-39; GAPDH: Fw: 59-AGCCACATCGCTCAGA-
CAC-39, Rev: 59-GCCCAATACGACCAAATCC-39. Values were calculated
using relative standard curves and normalized to GAPDH. Specificity of
the PCR products was confirmed by dissociation curve analysis.
*p,0.05.
doi:10.1371/journal.pone.0044598.g003
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underestimated BChE activity as substantial inhibition by the
presence of detergents occurs [25]. Because our main goal was to
describe how AChE is regulated in the cirrhotic liver, we used the
detergent Triton X-100 for cholinesterase extraction, which allows
a recovery of 80–90% of the total tissue AChE activity [19].
Further studies should better assess the degree of BChE activity in
the liver, since we can not rule out some inhibition by Triton X-
100 [25]. Nonetheless, to our knowledge, this is the first report
indicating that serum BChE decreases in t withhe livers of patients
with end-stage liver disease (ie, cirrhosis).
We have previously described a marked decrease in serum and
liver AChE levels, with no changes in BChE levels, in a cirrhotic
rat model [13]. This change was associated with a selective loss of
the tetrameric form of AChE. Thus, in cirrhotic conditions, the
expression of both cholinesterases is differentially affected between
humans and rats. These differences are not apparent when all the
molecular forms of both cholinesterases are considered collective-
ly. In the liver and serum, tetrameric forms and light species have
been identified for both, AChE and BChE. However, the level of
contribution of each form is dependent on the species being
studied. In humans the amount of BChE in plasma is much higher
than AChE, with a large amount of BChE tetramers and small
amounts of the light AChE species; while in rat serum tetrameric
AChE is the major cholinesterase species. The physiological
significance of cholinesterase activity in liver and serum has thus
far not been elucidated, but we can hypothesize that evolution-
arily, the same role has been performed by tetrameric AChE in
rats and by tetrameric BChE in humans. In both animal species
the depletion of tetramers, G4 BChE in humans or G4 AChE in
rats, is linked to chronic liver disease and probably reflects tissue
damage, although the physiological relevance is still to be
determined.
Despite the unchanged AChE activity in human cirrhotic liver
and serum we observed an increase in the immunoreactivity to
different anti-AChE antibodies by western blotting. This apparent
increase in AChE protein has been corroborated by immunohis-
tochemistry and, at expression level, is accompanied by an
increase of AChE transcripts. The majority of increased AChE
immunoreactivity is located within hepatocytes located at borders
surrounding regenerative nodules. Interestingly, AChE has been
proposed as a key predictor for hepatocellular carcinoma
prognosis [12]. The possibility that AChE participates in the
development of cancerous nodules requires further research.
Beside a role in the process of normal and pathological cell
proliferation, it is has been suggested that AChE might be also
involve in the promotion of various types of apoptosis, [26,27].
Moreover, a 55 kDa AChE protein results selectively induced
during apoptosis [28]. Thus, it is plausible that AChE participates
in hepatocellular apoptosis that characterizes cirrhosis. Further
functional studies should confirm this hypothesis.
Two aspects that should also be considered are the non-catalytic
nature of the increased AChE protein and the identity of the
species. First, as both active and inactive subunits of the protein
could contribute to the immunoreactivity of the bands, we can
logically assume that enzymatically inactive AChE protein species
are increased in the cirrhotic liver. AChE is present as both active
and inactive subunits and the inactive AChE molecules have been
described as lighter AChE molecules [14,15,16]. Interestingly, in
the rat model of cirrhosis, despite the overall decrease in AChE
activity due to tetramer depletion, we have also observed an
increase in some immunoreactive AChE band, which can be
attributed in part to inactive AChE, as well as to an increase of the
R transcript [13], demonstrating again, similarities between the
cirrhotic rat model and the disease in humans. The presence of an
inactive catalytic pool of AChE, which is increased in the cirrhotic
liver, suggests AChE may have roles in the liver independent of its
enzymatic activity. Multiple activities of AChE include non-
classical actions that are independent of the catalytic capacity, thus
catalytically inactive AChE species may still be physiologically
active. The inactive AChE fraction is abundant in embryonic
tissues [2] where a cholinergic function has thus far not been
attributed. It has also been demonstrated that transgenic
overexpression of enzymatically inactive AChE can influence
neurodevelopment [29]. Indeed, AChE levels are routinely
estimated enzymatically and not immunochemically. As such,
little information is available on this non-catalytic pool of AChE in
both pathological and non-pathological conditions. Whether non-
catalytic AChE in liver has physiological significance, and how it is
affected during pathology, are issues that warrant further study.
It is also important to further define the nature of the AChE
species which is increased in liver cirrhosis. AChE exhibits high
molecular polymorphism contributed as a result of alternative
splicing. AChE exists in different isoforms, with the same catalytic
domain but with distinct C-terminal peptides. These splice
variants may have different and specific functions [30], dependent
on their specific subcellular localization. Alternatively, specific
properties associated to the particular C-terminus of AChE may
modulate binding affinities for other interacting proteins, etc. Our
data demonstrates that the major liver AChE species, the 55 kDa
subunits, correspond to both R- and T-subunits, as react with
specific antibodies. Although the predicted molecular weight of the
AChE subunits is ,70 kDa in size, our as well as other studies
strongly suggest the specificity identity of lower AChE molecular
weight bands [10,13,21,28,31,32]. The specificity of these AChE
Figure 4. Immunopositive acetylcholinesterase (AChE) staining
in cirrhotic human liver. Representative photographs of liver
specimens from a control subject (NL) and a patient with hepatitis C
virus (HCV)-induced cirrhosis (CL), stained for AChE (antibody N19).
Weak immunopositive AChE was mainly localized in normal hepato-
cytes. This immunoreactivity was clearly increased in the cirrhotic liver,
especially in hepatocytes preferentially located at borders surrounding
regenerative liver nodules (arrows).
doi:10.1371/journal.pone.0044598.g004
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bands was confirmed by immunoblotting plasma samples with the
anti-human AChE N-terminal antibody, N-19, and the T548
antibody. R- and T-subunits of this size are present in different
human tissues with the exception of red-blood cells, which possess
only H-subunits [10]. The presence of the H-subunit was not
assessed in plasma due to the lack of specific antibodies. Analysis of
the levels of liver AChE transcripts indicated that all AChE
molecular isoforms appear to be similarly altered in liver cirrhosis.
We were able to determine an increase in the AChE-R specie in
cirrhotic serum, while levels of soluble AChE-T remain unaltered.
The relatively rare AChE-R is an ubiquitous protein present at
low levels in many, if not all, tissues (similar to the more common
AChE-T specie); and is classically induced under psychological,
chemical or physical stress [33]. The AChE-R can display distinct
and sometimes an inverse function to the major AChE-T species
(see for example [34]), and can also interact with specific partners
such as the scaffold protein RACK1 [34], the kinase PKCbeta II
[35], or the glycolytic enzyme enolase [34]. Over-expression of
AChE-R has been associated with germ cell apoptosis [36],
hematopoietic proliferation [37], and in abnormal cells correlated
with cell proliferation [38]. In particular, AChE-R is elevated in
various tumor types [39], and in other diverse pathological
conditions such as oxidative stress [40] and behavioral impairment
[41], among others. The significance of the increase in the stress-
induced R-AChE in cirrhotic serum is unclear and further studies
of the relationship between the AChE-R specie and liver
pathology are still needed.
In conclusion, this is the first study to reliably demonstrate that liver
disease affects the expression and levels of AChE in human liver and
serum. The possibility to monitor changes not only in serum BChE
activity, but also in the soluble AChE-R, as a function of liver disease
progression and prognosis requires further consideration.
Supporting Information
Figure S1 Decreased levels of plasma butyrylcholines-
terase (BChE) activity in cirrhotic individuals. (A) Plasma
from non-diseased controls (NL) and individuals with liver
cirrhosis (CL) (same cases that in Fig. 1) assayed for BChE activity
(before immunoprecipitation), displayed diminished levels in CL.
(B) Sedimentation analysis displays a decrease in the major BChE
tetrameric forms (G4) which decrease in CL (#), in comparison
with normal liver (N).* p,0.05 significantly different from NL, as
assessed by Student’s t-test.
(TIF)
Figure S2 Immunodetection of AChE subunits with the
antibody T548. (A) Representative immunoblot of samples from
human plasma and cerebrospinal fluid (CSF), and from brain
(frontal cortex), red blood cells (RBCs), and liver extracts from non-
disease subjects were blotted with the T548 antibody. A
representative immunoblot with the antibody N-19 from a human
plasma sample is included (left panel). The antibody T548 confirms
the specificity of the 66 and 55 kDa bands, whereas the 78 kDa
subunit, revealed with the antibody N19, was non immunoreactive
to the antibody T548. (B) The specificity of T458 has been
demonstrated in brain extracts from wild-type and AChE knockout
mice (see ref. [24]), and confirmed here by blotting cortical brain
extracts from 11-month old AChE knockout mice (AChE2/2; see
[42]) and age-matched wild type controls (AChE+/+) (equivalent
amounts of protein were loaded in each lane).
(TIF)
Figure S3 Decreased liver butyrylcholinesterase (BChE)
activity in cirrhotic individuals. (A) Levels of liver BChE
from non-diseased subjects (NL) and cases with cirrhosis (CL)
(same cases as in Fig. 2) measured prior to BChE depletion,
displayed diminished levels in CL. * p,0.05. (B) The represen-
tative profiles of BChE molecular forms displays light monomers
and dimers (G1+G2), but also tetramers (G4). The decrease in
BChE activity in CL (#), in comparison with normal liver (N),
corresponds to a decrease in all molecular forms.
(TIF)
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